Biotechnology company Moderna (NASDAQ: MRNA) reported Q3 2026 results exceeding the market’s revenue expectations, with sales up 29.2% year on year to $1.31 billion. Its non-GAAP profit of $0.38 per share was significantly above analysts’ consensus estimates.

Is now the time to buy MRNA? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Moderna’s third quarter was marked by robust revenue growth, operational improvements, and a positive market response. Management attributed the strong results to higher-than-anticipated sales of COVID-19 vaccines, effective international expansion, and disciplined cost management. CEO Stéphane Bancel highlighted the successful launch of the mFLUSIVA influenza vaccine in the U.S. and Canada, along with positive phase III data for the company’s individualized cancer therapy, intismeran. The quarter also saw Moderna strengthen its financial position through a convertible debt financing and welcome back Juan Andres to its executive committee, reflecting a focus on expanding both its commercial and manufacturing capabilities.

Looking forward, Moderna’s guidance is shaped by the momentum in its respiratory vaccine portfolio and clinical advances in oncology. Management is focused on driving revenue growth through broader international partnerships and regulatory approvals for new vaccine products. CFO Jamey Mock emphasized ongoing cost discipline and efficiency gains as key to sustaining margins, while President Stephen Hoge pointed to pipeline progress—including upcoming regulatory filings and readouts in oncology and rare diseases—as major value drivers. Management continues to prioritize investment in its oncology franchise, with Bancel stating, “We are investing aggressively in our individualized cancer therapy platform and preparing for important regulatory submissions and milestone readouts in the coming quarters.”

Key insights from management’s remarks

Management credited the quarter’s performance to strong international execution, new product launches in respiratory vaccines, and a notable positive clinical milestone in oncology.

• COVID-19 vaccine momentum: Strong sales of mNEXSPIKE in both U.S. and international markets, supported by steady vaccination rates and strategic partnerships, drove commercial outperformance. Management noted that international revenue year-to-date surpassed the prior year’s total by $200 million, reflecting successful execution in Canada and the U.K.

• Respiratory portfolio expansion: Approvals of mFLUSIVA in the U.S. and Canada and mCOFLU in Canada expanded Moderna’s presence in the influenza vaccine market. The company also delivered updated COVID-19 vaccines globally, with regulatory reviews ongoing for combination products such as mCOMBRIAX.

• Oncology pipeline milestone: The phase III trial for intismeran, Moderna’s individualized cancer vaccine in partnership with Merck, showed a 42% reduction in risk of recurrence or death in resected melanoma patients, with even greater benefit in the modified intention-to-treat population. This represents the first positive phase III result for an individualized cancer vaccine.

• Financial discipline and capital raise: Management highlighted a $3 billion convertible debt issuance, with $2.6 billion in net proceeds after transaction fees, strengthening the balance sheet to fund pipeline growth, particularly in oncology.

• Leadership return: The return of Juan Andres to the executive committee, following his prior role in scaling global manufacturing, was described as a key step as Moderna enters a new phase of commercial and pipeline expansion.

Drivers of future performance

Moderna’s updated outlook is anchored in continued vaccine adoption, cost discipline, and clinical progress in oncology and rare diseases.

• Broader vaccine adoption: Management expects international partnerships and new product approvals in respiratory vaccines—including expanded launches of mFLUSIVA and mCOMBRIAX—to drive revenue growth. Ongoing regulatory reviews in major global markets are expected to further support this trend.

• Oncology expansion: The company is prioritizing investment in individualized cancer therapies, with the intismeran BLA filing and event-driven clinical readouts in renal cell carcinoma and rare diseases seen as upcoming catalysts. Management highlighted potential for intismeran in additional tumor types, and the ongoing expansion of phase II and III oncology studies.

• Cost control and capital allocation: Continued reductions in R&D and capital expenditures, alongside operational efficiencies, are expected to support margin improvement and maintain a strong cash position. Management cautioned that future growth depends on sustained vaccine uptake and successful regulatory outcomes.

Catalysts in upcoming quarters

In the quarters ahead, the StockStory team will be watching (1) progress on regulatory submissions and launches for new respiratory vaccines, (2) the timing and outcomes of phase II and III oncology trial readouts—particularly in renal cell carcinoma, lung cancer, and rare diseases, and (3) further international expansion and execution of strategic partnerships. Sustained cost efficiencies and cash management will also be critical for tracking Moderna’s ability to reinvest in pipeline growth.

Moderna currently trades at $256.75, up from $241.46 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).

Our favorite stocks right now

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.